Corium Archives - Medical Design Sourcing

Corium touts study results for once-daily ADHD capsule

Corium (NSDQ:CORI) today announced clinical data demonstrating the strong performance of its once-daily ADHD capsule.

Boston-based Corium’s Azstarys oral capsule for treating ADHD symptoms (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) received FDA approval in March as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients aged six years and older.

Get the full story at our sister site, Drug Delivery Business News.

FDA to make decision on Corium’s transdermal patch for treating dementia next year

Corium (NSDQ:CORI) announced today that the FDA set a Prescription Drug User Fee (PDUFA) target action date for its Adlarity system.

The FDA set the PDUFA target action date for Adlarity (donepezil transdermal system), a transdermal patch designed to treat dementia or Alzheimer’s disease, for March 11, 2022.

Get the full story at our sister site, Drug Delivery Business News.

FDA clears once-daily ADHD capsule from Corium

Corium (NSDQ:CORI) announced today that it received FDA approval for its once-daily Azstarys oral capsule for treating ADHD symptoms.

Boston-based Corium touts its Azstarys (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) drug as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients aged six years and older, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.